Role of a Risk of Malignancy Index in Clinical Approaches to Adnexal Masses |
Simsek, Hakki Sencer
(Dr. Zekai Tahir Burak Women's Health Research and Education Hospital, Department of Obstetrics and Gynecology)
Tokmak, Aytekin (Dr. Zekai Tahir Burak Women's Health Research and Education Hospital, Department of Obstetrics and Gynecology) Ozgu, Emre (Dr. Zekai Tahir Burak Women's Health Research and Education Hospital, Department of Obstetrics and Gynecology) Doganay, Melike (Dr. Zekai Tahir Burak Women's Health Research and Education Hospital, Department of Obstetrics and Gynecology) Danisman, Nuri (Dr. Zekai Tahir Burak Women's Health Research and Education Hospital, Department of Obstetrics and Gynecology) Erkaya, Salim (Dr. Zekai Tahir Burak Women's Health Research and Education Hospital, Department of Obstetrics and Gynecology) Gungor, Tayfun (Hitit University, Department of Obstetrics and Gynecology) |
1 | Ashrafgangooei T, Rezaeezadeh M (2011). Risk of malignancy index in preoperative evaluation of pelvic masses. Asian Pac J Cancer Prev, 12, 1727-30. |
2 | Andersen ES, Knudsen A, Rix P, Johansen B (2003). Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol, 90, 109-12. DOI ScienceOn |
3 | Arun-Muthuvel V, Jaya V (2014). Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound. Asian Pac J Cancer Prev, 15, 2929-32. 과학기술학회마을 DOI ScienceOn |
4 | Bast RC Jr, Feeney M, Lazarus H, et al (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 68, 1331-7. DOI |
5 | Bell R, Petticrew M, Sheldon T (1998). The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol, 105, 1136-47. DOI |
6 | Bian J, Li B, Kou XJ, Liu TZ, Ming L (2013). Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev, 14, 6241-3. 과학기술학회마을 DOI ScienceOn |
7 | Davies AP, Jacobs IJ (1993). The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol, 100, 927-31. DOI |
8 | Klug TL, Bast RC Jr, Niloff JM, et al (1984). Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinomas. Cancer Res, 44, 1048-53. |
9 | Disaia J.P, Creasman W.T (2012). Clinical Gynecologic Oncology, 8th edition, Chapter. The Adnexal Mass, 212-13. |
10 | Geomini P, Kruitwagen R, Bremer GL, et al (2009). The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol, 113, 384-94. DOI ScienceOn |
11 | Jacobs I, Oram D, Fairbanks J, et al (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol, 97, 922-9. DOI ScienceOn |
12 | Lin JY, Qin JB, Li XY, et al (2012). Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5427-32. 과학기술학회마을 DOI ScienceOn |
13 | Ma S, Shen K, Lang J (2003). A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J, 116, 396-9. |
14 | Manjunath AP, Pratapkumar, Sujatha K, Vani R (2001). Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol, 81, 225-9. DOI ScienceOn |
15 | Mathevet P, Delaloye JF (2013). Ovarian cancer screening in the general population. Rev Med Suisse, 9, 1943-4. |
16 | Obeidat BR, Amarin ZO, Latimer JA, Crawford RA (2004). Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet, 85, 255-8. DOI ScienceOn |
17 | Terzic M, Dotlic J, Likic I, et al (2013). Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. Taiwan J Obstet Gynecol, 52, 253-7. DOI ScienceOn |
18 | Sayasneh A, Wynants L, Preisler J, et al (2013). Multicentre external validation of IOTA prediction models and RMI by operators with varied training. Br J Cancer, 108, 2448-54. DOI ScienceOn |
19 | Tongsong T, Wanapirak C, Neeyalavira V, et al (2009). E-flow doppler indices for prediction of benign and malignant ovarian tumors. Asian Pac J Cancer Prev, 10, 139-42. |
20 | Su Z, Graybill WS, Zhu Y (2013). Detection and monitoring of ovarian cancer. Clin Chim Acta, 415, 341-5. DOI ScienceOn |
21 | Tingulstad S, Hagen B, Skjeldestad FE, et al (1999). The riskof-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol, 93, 448-52. DOI ScienceOn |
22 | Wanapirak C, Srisupundit K, Tongsong T (2006). Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses. Asian Pac J Cancer Prev, 7, 407-10. |
23 | Winarto H, Laihad BJ, Nuranna L (2014). Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev, 15, 1949-53. 과학기술학회마을 DOI ScienceOn |
24 | Yavuzcan A, Caglar M, Ozgu E, et al (2013). Should cutoff values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations? Asian Pac J Cancer Prev, 14, 5455-9. DOI ScienceOn |
25 | Yamamoto Y, Yamada R, Oguri H, et al (2009). Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstets Gynecol Reproductive Biology, 144, 163-7. DOI ScienceOn |
![]() |